New flu pill TRX-100 put to the test in human challenge trial

NCT ID NCT07503405

Not yet recruiting Disease control Sponsor: Traws Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single oral dose of TRX-100 can prevent influenza infection in healthy adults aged 18 to 55. Participants will be deliberately exposed to the flu virus in a controlled setting. The trial is randomized, double-blind, and placebo-controlled, meaning neither participants nor researchers know who gets the real drug. The main goal is to see if TRX-100 reduces the number of lab-confirmed flu infections and moderate-to-severe symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tivoxavir marboxil (TRX-100)
What this could lead to: If successful, this could point toward a new oral medication to prevent influenza infection after exposure.
What could go wrong: This is an early Phase 2a proof-of-concept study with only 165 participants, so results may not apply broadly. The drug is tested in a controlled challenge model, not real-world conditions, and may fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA

Contacts and locations

Locations

hVIVO Services Limited

London, E14 5NR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.